Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
SANTA MONICA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today…
Hour9 Launches AI Automation Agency with Process-First Approach, Challenging Assumption That Businesses Should Maximize AI Integration
Sixty-Six Capital Expands Effective Bitcoin Exposure with Option for up to 200 BTC and Move to Direct Holdings
NTG Clarity to Announce Second Quarter Financial Results on August 27, 2026 with Earnings Call to Follow
SonicStrategy Reports Q2 2026 Staking Revenue and Reduced Monthly Burn
QSE Closes Second Tranche of Private Placement of $6 Million